[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,331,637
  • Shares Outstanding, K 231,773
  • Annual Sales, $ 510,170 K
  • Annual Income, $ 146,930 K
  • EBIT $ 215 M
  • EBITDA $ 224 M
  • 60-Month Beta 0.74
  • Price/Sales 4.21
  • Price/Cash Flow 14.16
  • Price/Book 5.51

Options Overview Details

View History
  • Implied Volatility 51.71% (-4.02%)
  • Historical Volatility 40.73%
  • IV Percentile 15%
  • IV Rank 11.31%
  • IV High 147.60% on 03/27/26
  • IV Low 39.48% on 01/22/26
  • Expected Move (DTE 14) 0.55 (5.58%)
  • Put/Call Vol Ratio 0.42
  • Today's Volume 371
  • Volume Avg (30-Day) 872
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 72,470
  • Open Int (30-Day) 70,110
  • Expected Range 9.35 to 10.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.19
  • Number of Estimates 1
  • High Estimate $0.19
  • Low Estimate $0.19
  • Prior Year $0.16
  • Growth Rate Est. (year over year) +18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.16 +21.25%
on 07/24/26
10.35 -4.35%
on 08/06/26
+0.69 (+7.49%)
since 07/07/26
3-Month
7.45 +32.89%
on 06/02/26
10.35 -4.35%
on 08/06/26
+1.43 (+16.88%)
since 05/07/26
52-Week
7.21 +37.31%
on 03/26/26
20.46 -51.61%
on 12/12/25
-6.85 (-40.90%)
since 08/07/25

Most Recent Stories

More News
ADMA Biologics 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 10, 2026 ...

ADMA : 9.90 (-1.59%)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 7, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors...

ADMA : 9.90 (-1.59%)
ADMA Biologics Deadline: Rosen Law Firm Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm – ADMA

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class...

ADMA : 9.90 (-1.59%)
MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO , Aug. 7, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP  announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between...

ADMA : 9.90 (-1.59%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA

NEW YORK , Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are...

ADMA : 9.90 (-1.59%)
ADMA Biologics, Inc. Deadline: ADMA Investors with Losses in Excess of $100K Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK , Aug. 6, 2026 /PRNewswire/ --

ADMA : 9.90 (-1.59%)
ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN FRANCISCO , Aug. 6, 2026 /PRNewswire/ -- Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA)  that a securities fraud class action lawsuit has been filed. The lawsuit...

ADMA : 9.90 (-1.59%)
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES , Aug. 6, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP  ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics,...

ADMA : 9.90 (-1.59%)
ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA

LOS ANGELES , Aug. 5, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA ) for violations...

ADMA : 9.90 (-1.59%)
Adma Biologics: Q2 Earnings Snapshot

Adma Biologics: Q2 Earnings Snapshot

ADMA : 9.90 (-1.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 10.58
2nd Resistance Point 10.38
1st Resistance Point 10.14
Last Price 9.90
1st Support Level 9.70
2nd Support Level 9.51
3rd Support Level 9.27

See More

52-Week High 20.46
Fibonacci 61.8% 15.40
Fibonacci 50% 13.83
Fibonacci 38.2% 12.27
Last Price 9.90
52-Week Low 7.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.